View in EDS HTML Full Text PDF Full Text

Case report: PD-L1-targeted high-affinity natural killer cells and IL-15 superagonist N-803-based therapy extend overall survival of advanced metastatic pancreatic cancer patients.

Saved in:
Bibliographic Details
Title: Case report: PD-L1-targeted high-affinity natural killer cells and IL-15 superagonist N-803-based therapy extend overall survival of advanced metastatic pancreatic cancer patients.
Authors: Seery T; Chan Soon-Shiong Institute for Medicine, El Segundo, CA, United States., Sender L; ImmunityBio Inc., Culver City, CA, United States., Jafari O; Medical Imaging Center of Southern California, Santa Monica, CA, United States., Jones F; NantCell, Culver City, CA, United States., Spilman P; ImmunityBio Inc., Culver City, CA, United States., Reddy SB; ImmunityBio Inc., Culver City, CA, United States., Soon-Shiong P; ImmunityBio Inc., Culver City, CA, United States.
Source: Frontiers in oncology [Front Oncol] 2025 Jan 29; Vol. 15, pp. 1472714. Date of Electronic Publication: 2025 Jan 29 (Print Publication: 2025).
Publication Type: Case Reports; Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39944830
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Case report: PD-L1-targeted high-affinity natural killer cells and IL-15 superagonist N-803-based therapy extend overall survival of advanced metastatic pancreatic cancer patients.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Seery+T%22">Seery T</searchLink>; Chan Soon-Shiong Institute for Medicine, El Segundo, CA, United States.<br /><searchLink fieldCode="AU" term="%22Sender+L%22">Sender L</searchLink>; ImmunityBio Inc., Culver City, CA, United States.<br /><searchLink fieldCode="AU" term="%22Jafari+O%22">Jafari O</searchLink>; Medical Imaging Center of Southern California, Santa Monica, CA, United States.<br /><searchLink fieldCode="AU" term="%22Jones+F%22">Jones F</searchLink>; NantCell, Culver City, CA, United States.<br /><searchLink fieldCode="AU" term="%22Spilman+P%22">Spilman P</searchLink>; ImmunityBio Inc., Culver City, CA, United States.<br /><searchLink fieldCode="AU" term="%22Reddy+SB%22">Reddy SB</searchLink>; ImmunityBio Inc., Culver City, CA, United States.<br /><searchLink fieldCode="AU" term="%22Soon-Shiong+P%22">Soon-Shiong P</searchLink>; ImmunityBio Inc., Culver City, CA, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2025 Jan 29; Vol. 15, pp. 1472714. <i>Date of Electronic Publication: </i>2025 Jan 29 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Case Reports; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39944830
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2025.1472714
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1472714
    Titles:
      – TitleFull: Case report: PD-L1-targeted high-affinity natural killer cells and IL-15 superagonist N-803-based therapy extend overall survival of advanced metastatic pancreatic cancer patients.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Seery T
      – PersonEntity:
          Name:
            NameFull: Sender L
      – PersonEntity:
          Name:
            NameFull: Jafari O
      – PersonEntity:
          Name:
            NameFull: Jones F
      – PersonEntity:
          Name:
            NameFull: Spilman P
      – PersonEntity:
          Name:
            NameFull: Reddy SB
      – PersonEntity:
          Name:
            NameFull: Soon-Shiong P
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 29
              M: 01
              Text: 2025 Jan 29
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 15
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1